Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Phase 3
2(40.0%)
Phase 4
1(20.0%)
5Total
Phase 2(2)
Phase 3(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01975480Phase 4Completed

Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities

Role: lead

NCT02072187Phase 3Terminated

Adjunctive Vitamin D in the Treatment of Non-remitted Depression

Role: lead

NCT00773162Phase 3Completed

Flushing in Social Anxiety Disorder on Seroquel

Role: lead

NCT00485888Phase 2Completed

Flushing in Social Anxiety Disorder on Cipralex

Role: lead

NCT00485615Phase 2Completed

An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia

Role: lead

All 5 trials loaded